U.S. Court in Connecticut Says Brand-Name Drug Maker Can Be Liable for Injuries Caused by Bio-Equivalents
- June 17, 2022
The U.S. District Court for the District of Connecticut adopted a theory of innovator liability in holding that drug manufacturer Glaxosmithkline (GSK) can be held liable for injuries caused by the generic equivalent one of its brand-name drugs.
ARTICLE TAGS
You must be logged in to access this content.